THERAPY DOSSIER · th-9bef22593855

Fimasartan (BR-A-657), an angiotensin II type 1 receptor blocker

Drug · Type-1 angiotensin II receptor antagonist (ANTAGONIST; direct interaction)

Evidence & regulatory context

Mechanism: Type-1 angiotensin II receptor antagonist (ANTAGONIST; direct interaction)
Target: CHEMBL227
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1951143 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Fimasartan; BR-A-657; Fimasartan potassium trihydrate; Kanarb
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02147704 ↗PHASE4completed

Sodium Intake on PK/PD of Fimasartan

Hypertension

Enrolment: 27 · Results not recorded

NCT05173025 ↗PHASE4unknown

Fimasartan or Amlodipine on Extended RAS in T2D and Hypertension

Hypertension · Atherosclerosis · Diabetes Mellitus, Type 2

Enrolment: 42 · Results not recorded

NCT02152306 ↗PHASE3completed

Fimasartan/Amlodipine vs Fimasartan Monotherapy in Essential Hypertension

Essential Hypertension

Enrolment: 143 · Results not recorded

NCT01007409 ↗PHASE1completed

Food Effect on PK of Fimasartan

Healthy

Enrolment: 24 · Results not recorded

NCT01146938 ↗PHASE1completed

PK/Safety of Fimasartan in Hepatic Impairment

Essential Hypertension · Hepatic Impairment

Enrolment: 18 · Results not recorded

NCT03250052 ↗PHASE1completed

PK Interaction Between Fimasartan and Linagliptin

Hypertension

Enrolment: 39 · Results not recorded

NCT02397590 ↗PHASE1completed

PK Interaction Between Fimasartan and Atorvastatin

Hypertension

Enrolment: 36 · Results not recorded

NCT05413057 ↗Nonerecruiting

Fimasartan/Amlodipine (+/-HCTZ) FDCs in Essential Hypertension

Hypertension, Essential

Enrolment: 20000 · Results not recorded

NCT04554953 ↗Nonecompleted

Fimasartan + Statins Combination in Hypertension and Dyslipidemia

Hypertension and Dyslipidemia

Enrolment: 10877 · Results not recorded

NCT03231293 ↗Nonecompleted

Fimasartan-based Treatment in Post-Acute Ischemic Stroke/TIA

Hypertension · Ischemic Stroke · Transient Ischemic Attack

Enrolment: 1035 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30171865 ↗2018Reported benefit

Pretreatment with low-dose fimasartan ameliorates NLRP3 inflammasome-mediated neuroinflammation and brain injury after intracerebral hemorrhage.

RatOtherSprague-DawleyMalen = 113 rats in total across five groups; n = 10 per group for…Oral (p.o.); dissolved in phosphate-buffered saline at 1 mg/mL and diluted with sterile waterLow dose 0.5 mg/kg; regular doses 1.0 and 3.0 mg/kg. In vit…Pretreatment for 30 days before induction of intracerebral haemorrhage

Model: Collagenase IV induced intracerebral haemorrhage, 0.6 U in 1 microlitre saline injected intrastriatally (3.0 mm left, 0.2 mm posterior to bregma, 6.0 mm depth)

Low-dose fimasartan (0.5 mg/kg) did not change mean blood pressure (97 mmHg versus 97 mmHg in control) yet reduced brain water content at 3 days (81.6 versus 82.0 per cent), improved mNSS at all time points and improved forelimb placing at day 3 (33.8 versus 25.6). It suppressed NF-kB and COX-2 act…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…